TABLE 1.
Number of Vaccinations Completed by Dosage Group
| Placebo (N=12) | 4 μg (N=16) | 20 μg (N=16) | 100 μg (N=16) | Total (N=60) | ||
|---|---|---|---|---|---|---|
| Vaccination number completed1 (Vaccination timepoints) | Dose 1 (Day 0) | 12 (100%) | 16 (100%) | 16 (100%) | 16 (100%) | 60 (100%) |
| Dose 2 (Week 4) | 11 (91.7%) | 15 (93.7%) | 14 (87.5%) | 16 (100%) | 56 (93.3%) | |
| Dose 3 (Week 24) | 8 (66.7%) | 14 (87.5%) | 14 (87.5%) | 16 (100%) | 52 (86.7%) | |
| Dose 4 (Week 48) | 8 (66.7%) | 14 (87.5%) | 14 (87.5%) | 14 (87.5%) | 50 (83.3%) | |
1
Ten subjects were withdrawn from the study after enrollment. The reasons for withdrawal included breast cancer, mental illness not reported at the time of enrollment, steroid use for contact dermatitis and tendonitis (2 subjects), fear of contracting cancer due to vaccine receipt, moved out of the area, noncompliance (4 subjects).